A sulfonyl fluoride derivative inhibits EGFR L858R/T790M/C797S by covalent modification of the catalytic lysine

The emergence of the C797S mutation in EGFR is a frequent mechanism of resistance to osimertinib in the treatment of non-small cell lung cancer (NSCLC). In the present work, we report the design, synthesis and biochemical characterization of UPR1444 (compound 11), a new sulfonyl fluoride derivative...

Full description

Saved in:
Bibliographic Details
Published in:European journal of medicinal chemistry 2021-12, Vol.225, p.113786
Main Authors: Ferlenghi, Francesca, Scalvini, Laura, Vacondio, Federica, Castelli, Riccardo, Bozza, Nicole, Marseglia, Giuseppe, Rivara, Silvia, Lodola, Alessio, La Monica, Silvia, Minari, Roberta, Petronini, Pier Giorgio, Alfieri, Roberta, Tiseo, Marcello, Mor, Marco
Format: Article
Language:English
Subjects:
Animals
Biocatalysis
Cell Proliferation - drug effects
Cell Survival - drug effects
Cells, Cultured
Dose-Response Relationship, Drug
ErbB Receptors - antagonists & inhibitors
ErbB Receptors - genetics
ErbB Receptors - metabolism
Humans
Lysine - antagonists & inhibitors
Lysine - metabolism
Mice
Models, Molecular
Molecular Structure
Protein Kinase Inhibitors - chemical synthesis
Protein Kinase Inhibitors - chemistry
Protein Kinase Inhibitors - pharmacology
Structure-Activity Relationship
Sulfinic Acids - chemical synthesis
Sulfinic Acids - chemistry
Sulfinic Acids - pharmacology
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The emergence of the C797S mutation in EGFR is a frequent mechanism of resistance to osimertinib in the treatment of non-small cell lung cancer (NSCLC). In the present work, we report the design, synthesis and biochemical characterization of UPR1444 (compound 11), a new sulfonyl fluoride derivative which potently and irreversibly inhibits EGFR through the formation of a sulfonamide bond with the catalytic residue Lys745. Enzymatic assays show that compound 11 displayed an inhibitory activity on EGFR comparable to that of osimertinib, and it resulted more selective than the sulfonyl fluoride probe XO44, recently reported to inhibit a significant part of the kinome. Neither compound 11 nor XO44 inhibited EGFR triple mutant. When tested in Ba/F3 cells expressing EGFR , compound 11 resulted significantly more potent than osimertinib at inhibiting both EGFR autophosphorylation and proliferation, even if the inhibition of EGFR autophosphorylation by compound 11 in Ba/F3 cells was not long lasting.
ISSN:1768-3254